Funding for this research was provided by:
National Institutes of Health (U01HG010218, U41HG009649, R01DK116750, R01DK120565, P30DK116074)
Article History
Received: 9 June 2021
Accepted: 10 February 2022
First Online: 28 February 2022
Declarations
:
: Not applicable.
: Not applicable.
: EAA is co-founder to Personalis, DeepCell, Svexa; non-executive director to AstraZeneca and advisor to Genome Medical, Sequence Bio, Apple, Foresite Capital. The remaining authors declare that they have no competing interests.